Floatz Rating
B58/100
Confidence
Indicative
Sponsor
University Health Network, Toronto
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06813079CT.gov Using Tumor Models to Determine Treatments | — | Not Yet Recruiting | — | — | — |
NCT06239467CT.gov First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | — | Recruiting | — | — | — |
NCT05785741CT.gov A Study of DB-1310 in Advanced/Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05525858CT.gov KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | — | Recruiting | — | — | — |
NCT05143970CT.gov A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05081609CT.gov A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT05159245CT.gov The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | — | Recruiting | — | — | — |
NCT04464967CT.gov Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | — | Withdrawn | — | — | — |
NCT04487236CT.gov Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors | — | Completed | — | — | — |
NCT05593094CT.gov A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
Show 19 more trialsShow fewer
NCT04172259CT.gov ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | — | Active Not Recruiting | — | — | — |
NCT03297606CT.gov Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | — | Recruiting | — | — | — |
NCT03319459CT.gov FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03013218CT.gov A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | — | Completed | — | — | — |
NCT02735798CT.gov 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets | — | Withdrawn | — | — | — |
NCT02693535CT.gov TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | — | Recruiting | — | — | — |
NCT02318901CT.gov Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | — | Terminated | — | — | — |
NCT00397501CT.gov BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain | — | Withdrawn | — | — | — |
NCT01454804CT.gov Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT01235897CT.gov MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | — | Completed | — | — | — |
NCT01077648CT.gov Brain Metastasis in Breast Cancer Patients | — | Completed | — | — | — |
NCT00968968CT.gov Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone | — | Terminated | — | — | — |
NCT00963547CT.gov A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | — | Terminated | — | — | — |
NCT00807859CT.gov Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00706095CT.gov Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System | — | Completed | — | — | — |
NCT00326950CT.gov Phase I Clinical Study of E7389 | — | Completed | — | — | — |
NCT00069264CT.gov Study of E7389 in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00069277CT.gov Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00005842CT.gov Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Trastuzumab (this asset) | University Health Network, Toronto | P3 | B · 58 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Trastuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 76 |
| Inflammatory Breast Carcinoma | — | P3 | BBB · 74 |
| HER2 Positive Breast Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Trastuzumab in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/trastuzumab-cancer-95358
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →